In a significant policy move, the Central Government has approved an emergency price hike for vital chemotherapy drugs, specifically Cisplatn and Carboplatin, which are foundational to cancer treatment. The National Pharmaceutical Pricing Authority (NPPA) issued the directives following a sharp, nationwide shortage of these life-saving medications. While the decision aims to incentivize pharmaceutical companies to ramp up production and stabilize the disrupted domestic supply chain, it is expected to immediately increase the financial burden on patients undergoing treatment.
The severe shortage was triggered by a dramatic escalation in the cost of raw platinum, a precious metal essential for manufacturing the active pharmaceutical ingredients (APIs) of these specific drugs. Geopolitical conflicts in West Asia, shipping disruptions along the Strait of Hormuz, and production deficits in major exporting nations like South Africa caused raw material expenses to double over the last six months. Because these essential medicines were under strict government price control mechanisms, local pharmaceutical firms found it financially unviable to continue manufacturing them under old price caps, leading to severe supply bottlenecks at major oncology centers.
The sudden price revision has sparked widespread concern among health experts, cancer patients, and their families, who are already struggling with the exorbitant costs of cancer care. While medical professionals acknowledge that a price hike is a necessary intervention to bring the life-saving drugs back onto hospital shelves, they emphasize the urgent need for safety nets. Health advocates are calling on the government to introduce targeted subsidies or alternative financial relief programs to ensure that underprivileged patients are not priced out of their critical, time-sensitive chemotherapy cycles.
